The Trump administration is ending subsidies that have helped lower prescription drug premiums for millions of older Americans under Medicare. The move, confirmed by two separate reports, is expected to increase costs for many beneficiaries starting next year.
The subsidies were part of a program that held down the cost of Medicare Part D premiums, which cover prescription drugs. Without these payments, insurance companies could raise premiums to offset the loss of federal support. Experts cited in the reports predict that the change will particularly affect seniors who rely on stand-alone drug plans, potentially prompting more to switch to Medicare Advantage plans, which often bundle drug coverage with other benefits.
The New York Times reported that the decision could hit millions of older Americans. MarketWatch added that analysts believe the shift may accelerate enrollment in Medicare Advantage, a private alternative to traditional Medicare. The timing of the change coincides with the upcoming open enrollment period, giving seniors limited time to adjust their coverage choices.
The administration has defended the move as part of broader efforts to reduce federal spending on healthcare, but critics argue it will place an additional burden on retirees with fixed incomes. The exact financial impact on individual premiums will vary by region and plan, but beneficiaries are advised to review their options during the enrollment window.